Status:
TERMINATED
Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens
Lead Sponsor:
Vivian Wing Yan Lee
Collaborating Sponsors:
Hoffmann-La Roche
Queen Elizabeth Hospital, Hong Kong
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective time-and-motion study to document and compare the time used in preparation, dispensing and administration for capecitabine/oxaliplatin (XELOX) versus IV 5-FU/leucovorin/oxaliplat...
Detailed Description
Colorectal cancer (CRC) is the second most common cause of cancer-related death in Hong Kong. The traditional chemotherapy for CRC remains on intravenous (IV) fluorouracil (5-FU) based regimens with t...
Eligibility Criteria
Inclusion
- Age 18 or above
- Diagnosed with CRC and prescribed with either XELOX for FOLFOX4 chemotherapy treatment
Exclusion
- Patients less than 18 years of age
- Persons related unequally to investigators
- Patients who are mentally/cognitively disabled
- Patients who refuse to give consent to participate
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01801085
Start Date
October 1 2011
End Date
December 1 2014
Last Update
February 2 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Kowloon, Hong Kong
2
Queen Elizabeth Hospital
Kowloon, Hong Kong